Business & regional news

Now supported with effectiveness evidence, Medtronic DBS is the first and only U.S. FDA approved system to treat Dystonia symptoms

The pivotal Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial demonstrates global clinical effectiveness, long-term safety, and patient preference

Minimally invasive laser technology now with enhanced capital system improvements, offering new user interface, workflow efficiencies, and upgrade capabilities

Study shows 67% mean reduction in Low-back Visual Analog Scale (VAS) pain score at 12 months; 87% of subjects had meaningful improvements in three or more quality of life (QoL) domains

Data to be presented at the North American Neuromodulation Society (NANS) Annual Meeting 2025; In all, Medtronic to highlight 22 poster and oral scientific data presentations

ADAPT-PD trial methods and preliminary data published in npj Parkinson’s disease

New MRI labeling extends active scan time for Medtronic DBS systems

First ever FDA approval provides more options to meet patients’ personalized needs, including those with Parkinson’s disease

Deal expands Pain Interventions portfolio, now offering both unipedicular and bipedicular vertebral augmentation solutions

Doubled probe count enables multi-level spine tumor ablations for increased flexibility and efficiency Medtronic plc, a global leader in healthcare technology, today announced that it has received...

86% of subjects preferred closed-loop SCS in a multicenter, randomized, crossover, single blind study of Medtronic’s investigational closed-loop SCS system at one month

24-month European RCT data demonstrates long-term superiority of DTM™ SCS compared with conventional medical management (CMM) for indicated chronic back pain patients not eligible for spine surgery

NOVA Study: On-label, prospective, multicenter, randomized controlled trial compared DTM™ SCS to conventional spinal cord stimulation

Prospective study will evaluate the long-term performance of the closed-loop algorithm and overall patient experience with Medtronic’s next generation, rechargeable spinal cord stimulation device